|

Marlotamig Clinical Trials

1 actively recruiting trial across 1 location

Also known as: REGN7075

Pipeline

Phase 2: 1

Top Sponsors

  • Regeneron Pharmaceuticals1

Indications

  • Advanced/Metastatic Non-Small Cell Lung Cancer1
  • Advanced Non-Small Cell Lung Cancer1
  • Metastatic Non-Small Cell Lung Cancer1
  • Carcinoma, Non-Small-Cell Lung1
  • Lung Cancer1

Birmingham, Alabama1 trial

A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

University of Alabama at Birmingham

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.